ADIL: 108% | Adial Pharmaceuticals shares are trading higher after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04.
NA: 70% | Nano Labs Files Annual Report on Form 20-F for Fiscal Year 2023
ABVC: 33% | ABVC BioPharma Executes A Global Licensing Term Sheet For Oncology/Hematology Products, Expecting Licensing Income Of $55M And Royalties Of Up To $50M